- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03774069
The Advisor Pro Direct Study
Evaluation of Remote Consultation to Patients With Type 1 Diabetes Under Continuous Glucose Sensors and Insulin Pump Therapy Using the DreaMed Advisor Pro. An Open Label, Randomized Non-inferiority Study of Insulin Pump Therapy Adjustments Between DreaMed Advisor Pro and Standard of Care-The Advisor Pro Direct Study
The DreaMed Advisor Pro is a software which automatically analyses treatment information, learns patient's needs and accordingly suggests adjustments in insulin dosing. DreaMed Advisor Pro is a decision- support software intended for assisting healthcare professionals in the management of type 1 diabetes patients who use insulin pumps as their insulin delivery therapy and monitor their blood glucose levels using CGM (Continuous Glucose Monitoring) or CGM and self-management blood glucose meter.
The main objective of the proposed study is to test the safety, reliability, and efficacy of the DreaMed Advisor Pro algorithm when the recommendation is sent directly to the patient without a physician review.
Participants will be randomized in a 1:1 ratio to either the intervention group (DreaMed Advisor Pro) or control group (standard of care). Participants will download the CGM and pump data at no less frequent than every 4 weeks for both groups during the 3 months period of the study.
Each time new data is received, the following actions will be performed:
In the intervention group, a new algorithm recommendation for pump settings will be issued. The recommendation will be approved by a technical, non-physician to assure that glucose data are not fall within predefined safety criteria which require a physician approval before the recommendation will be sent to the patient, otherwise, recommendation will be sent directly to the patient.
In the control group, if no safety criteria is met, it is the responsibility of the patient to contact his/her physician to advise on change of treatment. In case a safety issue has occurred, the physician will contact the patient and change the pump settings.
Prior to initiating the interventional phase of the study, we will evaluate the experience of patients in self adjustments of insulin dosing in regular care management and to evaluate their acceptance for using an automated dosing recommendations software. The evaluation will be done by asking patients/caregivers to fill 15 questions survey. 100 patients are anticipated to participate in this phase of the study.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Petach Tikva, Israel, 49202
- Schnider Children's medical center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Subject with type 1 diabetes (>1 yr diagnosis)
- Age- 6-30 years old
- HbA1c equals or above 7% and equals or below 10%
- Insulin infusion pump CSII (Continuous Subcutaneous Inulin Infusion) therapy for at least 4 months and current treatment with one of the following pumps: Omnipod Insulet (Bedford, MA), Medtronic Minimed Veo insulinPump (MMT-754, MMT-554), Medtronic 640G or Animas.
- BMI below 30 kg/m^2
- Patients willing to follow study instructions (willing to measure capillary blood glucose as required by their glucose sensor for calibration and use the bolus- calculator feature of the pump)
- Patients are required to have minimum computer skills and understanding of navigating the internet.
- Patients are required to know basic English.
- Patients willing to use glucose sensor for study duration.
- Patients will have to have a smartphone (Apple or Android) or PC with email account.
Exclusion Criteria:
- An episode of diabetic ketoacidosis within the month prior to study entry
- Any significant diseases/ conditions including psychiatric disorders and substance abuse that in the opinion of the investigator is likely to affect the subject's ability to complete the study or compromise patient's safety.
- Current participation in any other interventional study.
- Known or suspected allergy to trial products such as adhesives, tapes, needles.
- Female subject who is pregnant or lactating or planning to become pregnant within the planned study duration
- Severe hypoglycemia within six months prior to enrollment as defined by the ADA and Endocrine society as follows: Severe hypoglycaemia is an event requiring assistance of another person (due to change in mental status) to actively administer carbohydrates, glucagon, or take othe corrective actions.
- Current use of the following medications: medications that are use to lower blood glucose such as Pramlintide, Metformin and GLP-1 analogs. Beta blockers, glucocorticoids and other medications, which in the judgment of the investigator would be a contraindication to participation in the study.
- Hypoglycemia unawareness
Relevant severe organ disorders (diabetic nephropathy, diabetic retinopathy, diabetic foot syndrome) or any secondary disease or complication of diabetes mellitus.
- Subject has unstable or rapidly progressive renal disease or is receiving dialysis.
- Subject has active proliferative retinopathy.
- Active gastroparesis
- Patient suffers from eating disorder. -
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: DreaMed Advisor Pro
Insulin pump settings (i.e, basal plan, correction factor, carbohydrate ratio and insulin activity time) will be adjusted using the DreaMed Advisor pro.
|
Insulin pump settings (i.e, basal plan, correction factor, carbohydrate ratio and insulin activity time) will be adjusted using the DreaMed Advisor Pro and sent directly to the patient
|
Active Comparator: Control group- medical guided recommendation
Insulin pump settings (i.e, basal plan, correction factor, carbohydrate ration and insulin activity time) will be adjusted by the medical team
|
Insulin pump settings (i.e, basal plan, correction factor, carbohydrate ratio and insulin activity time) will be adjusted by the medical team according to standard of care
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Percentage of glucose readings within range of 70-180 mg/dl (3.9 to 10mmol/L)
Time Frame: Final visit (week 12)
|
Final visit (week 12)
|
Percentage of readings below 54 mg/dl (3.3 mmol/l)
Time Frame: Final visit (week 12)
|
Final visit (week 12)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
HbA1c
Time Frame: Final visit (week 12)
|
Final visit (week 12)
|
|
Diabetes treatment satisfaction questionnaire
Time Frame: Final visit (week 12)
|
The questionnaire contains 12-14 items (12 for the teens version and 14 for the parents version) the subscale for each items is from 0 to 6, and for most items the the higher the score, the greater the satisfaction with the treatment.Subscales are summed.
More specific instruction for analysis are detailed in Diabetologia 52:(suppl 1) S397, Abstruct 1013 and in a document named "Summary of recommended scoring" by Prof. Bradley, University of London
|
Final visit (week 12)
|
Percentage of glucose readings below 70 mg/dl (3.9 mmol/L)
Time Frame: Final visit (week 12)
|
Final visit (week 12)
|
|
Percentage of readings below 60 mg/dl (3.35mmol/L)
Time Frame: Final visit (week 12)
|
Final visit (week 12)
|
|
Percentage of readings above 180 mg/dl (10.0mmol/L)
Time Frame: Final visit (week 12)
|
Final visit (week 12)
|
|
percentage of readings above 250 mg/dl (13.9 mmol/L)
Time Frame: Final visit (week 12)
|
Final visit (week 12)
|
|
Area above the curve of glucose level of 180 mg/dl
Time Frame: Final visit (week 12)
|
Final visit (week 12)
|
|
Area above the curve of glucose level above180 mg/dl
Time Frame: Final visit (week 12)
|
Final visit (week 12)
|
|
Area under the curve of glucose level of 70 mg/dl
Time Frame: Final visit (week 12)
|
Final visit (week 12)
|
|
Area under the curve of glucose level below 70 mg/dl
Time Frame: Final visit (week 12)
|
Final visit (week 12)
|
|
Mean sensor blood glucose
Time Frame: Final visit (week 12)
|
Final visit (week 12)
|
|
Glucose variability measured by standard deviation
Time Frame: Final visit (week 12)
|
Final visit (week 12)
|
|
Number of recommendations sent to patient in the last 6 months prior to baseline and during intervention period
Time Frame: Final visit (week 12)
|
Final visit (week 12)
|
|
Number of recommendations for changes in settings per patient
Time Frame: Final visit (week 12)
|
Final visit (week 12)
|
|
Number of recommendations for changes in settings per iteration
Time Frame: Final visit (week 12)
|
Final visit (week 12)
|
|
Number of physician override Advisor recommendation
Time Frame: Final visit (week 12)
|
Final visit (week 12)
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- RMC040818ctil
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Type 1 Diabetes Mellitus
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
University of Colorado, DenverMassachusetts General Hospital; Beta Bionics, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Diabetes type1 | Type 1 Diabetes Mellitus | Autoimmune Diabetes | Diabetes Mellitus, Insulin-Dependent | Juvenile-Onset Diabetes | Diabetes, Autoimmune | Insulin-Dependent Diabetes Mellitus 1 | Diabetes Mellitus, Insulin-Dependent, 1 | Diabetes Mellitus, Brittle | Diabetes Mellitus, Juvenile-Onset and other conditionsUnited States
-
AstraZenecaCompletedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
University of California, San FranciscoJuvenile Diabetes Research FoundationCompletedType 1 Diabetes Mellitus | Diabetes Mellitus, Type I | Insulin-Dependent Diabetes Mellitus 1 | Diabetes Mellitus, Insulin-Dependent, 1 | IDDMUnited States, Australia
-
Capillary Biomedical, Inc.TerminatedType 1 Diabetes | Type 1 Diabetes Mellitus | Diabetes Mellitus, Type I | Diabetes Mellitus, Insulin-Dependent, 1 | IDDMAustria
-
National Institute of Allergy and Infectious Diseases...PPD; Rho Federal Systems Division, Inc.; Immune Tolerance Network (ITN)CompletedType 1 Diabetes Mellitus | T1DM | T1D | New-onset Type 1 Diabetes MellitusUnited States, Australia
-
Shanghai Changzheng HospitalRecruitingBrittle Type 1 Diabetes MellitusChina
-
Capillary Biomedical, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Type 1 Diabetes Mellitus | Diabetes Mellitus, Insulin-Dependent, 1Australia
-
Spiden AGDCB Research AGRecruitingType 1 Diabetes Mellitus | Type 1 Diabetes Mellitus With Hypoglycemia | Type 1 Diabetes Mellitus With HyperglycemiaSwitzerland
-
Instytut Diabetologii Sp. z o.o.National Center for Research and Development, Poland; Nalecz Institute of Biocybernetics...UnknownType 1 Diabetes Mellitus With Hyperglycemia | Type 1 Diabetes Mellitus With HypoglycaemiaPoland
Clinical Trials on DreaMed Advisor Pro
-
Rabin Medical CenterCompleted
-
Yale UniversityDreaMedWithdrawn
-
Rabin Medical CenterThe Leona M. and Harry B. Helmsley Charitable Trust; DreaMedCompletedType1 Diabetes MellitusUnited States, Germany, Israel, Slovenia
-
Rabin Medical CenterThe Leona M. and Harry B. Helmsley Charitable Trust; DreaMed DiabetesRecruiting
-
DreaMed DiabetesCompletedDiabetes Mellitus, Type 1 | Insulin-dependent Diabetes MellitusIsrael
-
NORCE Norwegian Research Centre ASHelse Sor-Ost; Sykehuset i Vestfold HFCompletedNeck Pain Musculoskeletal | Back Pain Lower BackNorway
-
Ottawa Hospital Research InstituteNot yet recruitingAirway ExtubationCanada
-
Ottawa Hospital Research InstituteRecruiting
-
Philips HealthcareCompletedClinical AlarmsGermany
-
Philips HealthcareYale UniversityCompletedClinical AlarmsUnited States